ORKA

Handel nachbörslich: 26.48 1.97 +8.04%

Oruka Therapeutics Inc (ORKA)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Oruka Therapeutics Inc

(720) 940-2200

10170 CHURCH RANCH WAY, WESTMINSTER

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ORKA's Discussions on Twitter

Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten

Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)

Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten

Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga

Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada

Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian

Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan

Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks

Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World

Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia

Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World

Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga

‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online

Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald

Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha

‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World

Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World

Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily

‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer

Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Leerink Partners starts drug developer Oruka with 'outperform' - XM

Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga

Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter

Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World

Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks

FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT

Oruka to advance psoriasis programs into clinic next year - BioWorld Online

Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK

Biotech firm enters $200M agreement - The Business Journals

Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada

Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com

Oruka Therapeutics secures $200 million in PIPE financing - Investing.com

Oruka Therapeutics secures $200 million in PIPE financing - Investing.com UK

Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire

Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire

Oruka Therapeutics Announces $200 Million Private Placement - StockTitan

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World

Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera

Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World

Oruka announces closing of merger with ARCA Biopharma - TipRanks

ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView

Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ORKA